MX2020013014A - N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. - Google Patents

N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Info

Publication number
MX2020013014A
MX2020013014A MX2020013014A MX2020013014A MX2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A
Authority
MX
Mexico
Prior art keywords
sup
benzamides
phenylsulfonyl
bcl
inhibitors
Prior art date
Application number
MX2020013014A
Other languages
English (en)
Inventor
Jianyong Chen
Shaomeng Wang
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2020013014A publication Critical patent/MX2020013014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente divulgación proporciona compuestos que tienen la Fórmula I-A: (ver Fórmula) y sus sales y solvatos aceptables desde el punto de vista farmacéutico, en donde A, X1, X2, X3 R1a, R1b, E, y (ver símbolo) son como se definen en la información de la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I-A para usar en el tratamiento de una enfermedad, trastorno o afección que responda a la inhibición de la proteína Bcl-2, como el cáncer.
MX2020013014A 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. MX2020013014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
MX2020013014A true MX2020013014A (es) 2021-02-22

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001391A MX2019001391A (es) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2020013014A MX2020013014A (es) 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001391A MX2019001391A (es) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Country Status (26)

Country Link
US (3) US10829488B2 (es)
EP (3) EP3569601B1 (es)
JP (2) JP6651180B2 (es)
KR (2) KR102429704B1 (es)
CN (2) CN109311871B (es)
AU (2) AU2017305508B2 (es)
BR (1) BR112019001666A2 (es)
CA (1) CA3031419C (es)
CY (1) CY1123859T1 (es)
DK (1) DK3494115T3 (es)
ES (1) ES2849959T3 (es)
HR (1) HRP20202073T1 (es)
HU (1) HUE053414T2 (es)
IL (2) IL264059B (es)
LT (1) LT3494115T (es)
MX (2) MX2019001391A (es)
PE (1) PE20190711A1 (es)
PH (1) PH12019500231A1 (es)
PT (1) PT3494115T (es)
RS (1) RS61821B1 (es)
RU (3) RU2744358C2 (es)
SA (1) SA519401020B1 (es)
SG (2) SG11201900135YA (es)
SI (1) SI3494115T1 (es)
WO (1) WO2018027097A1 (es)
ZA (2) ZA201900240B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
EP3569601B1 (en) * 2016-08-05 2022-06-22 The Regents of The University of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
MX2019012434A (es) 2017-04-18 2019-12-11 Shanghai Fochon Pharmaceutical Co Ltd Agentes inductores de apoptosis.
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
TWI725488B (zh) * 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3094449C (en) * 2018-07-31 2023-02-28 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
GEP20237460B (en) * 2018-07-31 2023-01-25 Ascentage Pharma Suzhou Co Ltd Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
WO2020103921A1 (en) * 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
WO2021000899A1 (en) * 2019-07-02 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
CN112294966B (zh) * 2019-07-31 2021-12-17 苏州亚盛药业有限公司 Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
TW202134239A (zh) * 2019-11-27 2021-09-16 大陸商蘇州亞盛藥業有限公司 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
EP3914251A4 (en) 2019-12-03 2022-03-23 Ascentage Pharma (Suzhou) Co., Ltd. N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS USED AS BCL-2 INHIBITORS
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
MX2022006631A (es) 2019-12-06 2022-09-07 Loxo Oncology Inc Dosificacion de un inhibidor de la tirosina cinasa de bruton.
WO2021175321A1 (en) 2020-03-06 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates
WO2021180040A1 (zh) * 2020-03-12 2021-09-16 南京明德新药研发有限公司 苯并五元环类化合物
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073707A (zh) * 2020-08-21 2022-02-22 苏州亚盛药业有限公司 治疗系统性红斑狼疮的组合物和方法
WO2022037683A1 (en) * 2020-08-21 2022-02-24 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20240016747A1 (en) * 2020-11-25 2024-01-18 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
US20240166644A1 (en) * 2021-02-01 2024-05-23 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 医薬組合せおよびその使用
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
KR20090087491A (ko) 2006-12-04 2009-08-17 아보트 러보러터리즈 암 치료요법을 위한 동반 진단 검정
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CR20160269A (es) 2008-12-05 2016-08-16 Abbvie Inc Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes
CN104945311A (zh) 2009-01-19 2015-09-30 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CA2751293A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
DK2435432T6 (da) * 2009-05-26 2023-12-18 Abbvie Ireland Unlimited Co Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
KR20180059560A (ko) * 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
MY191300A (en) 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
US10362975B2 (en) 2015-12-30 2019-07-30 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
EP3569601B1 (en) * 2016-08-05 2022-06-22 The Regents of The University of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Also Published As

Publication number Publication date
CN109311871A (zh) 2019-02-05
KR102376764B1 (ko) 2022-03-18
PT3494115T (pt) 2021-01-15
US20190315739A1 (en) 2019-10-17
PE20190711A1 (es) 2019-05-17
US20180354950A1 (en) 2018-12-13
ZA201908466B (en) 2020-05-27
RS61821B1 (sr) 2021-06-30
SA519401020B1 (ar) 2022-03-16
JP7205903B2 (ja) 2023-01-17
CA3031419A1 (en) 2018-02-08
KR102429704B1 (ko) 2022-08-04
EP3569601B1 (en) 2022-06-22
NZ750100A (en) 2021-01-29
LT3494115T (lt) 2021-01-25
KR20210107170A (ko) 2021-08-31
CN110483501A (zh) 2019-11-22
SI3494115T1 (sl) 2021-02-26
JP2020007311A (ja) 2020-01-16
AU2021202113B2 (en) 2022-08-18
BR112019001666A2 (pt) 2019-05-28
AU2021202113A1 (en) 2021-05-06
US20210002277A1 (en) 2021-01-07
JP2019527705A (ja) 2019-10-03
US10221174B2 (en) 2019-03-05
IL282099A (en) 2021-05-31
MX2019001391A (es) 2019-06-06
RU2020114660A3 (es) 2020-09-15
JP6651180B2 (ja) 2020-02-19
RU2722560C1 (ru) 2020-06-01
IL282099B (en) 2022-03-01
ES2849959T3 (es) 2021-08-24
EP3494115B1 (en) 2020-10-21
CN110483501B (zh) 2022-07-01
ZA201900240B (en) 2020-05-27
HRP20202073T1 (hr) 2021-02-19
HUE053414T2 (hu) 2021-06-28
WO2018027097A1 (en) 2018-02-08
RU2744358C2 (ru) 2021-03-05
CY1123859T1 (el) 2022-05-27
KR20190035710A (ko) 2019-04-03
CN109311871B (zh) 2020-02-28
CA3031419C (en) 2021-08-24
SG10201913643YA (en) 2020-03-30
US10829488B2 (en) 2020-11-10
IL264059A (en) 2019-01-31
EP4129999A1 (en) 2023-02-08
EP3569601A2 (en) 2019-11-20
PH12019500231A1 (en) 2019-07-29
US11718613B2 (en) 2023-08-08
EP3494115A1 (en) 2019-06-12
RU2020134802A (ru) 2022-04-25
SG11201900135YA (en) 2019-02-27
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
RU2020114660A (ru) 2020-06-19
IL264059B (en) 2021-05-31
AU2017305508A1 (en) 2019-02-07
EP3569601A3 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2017176957A8 (en) Mdm2 protein degraders
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020011089A (es) Compuestos antiproliferacion y usos de los mismos.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12021550258A1 (en) Cdk8/19 inhibitors
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors